For investors looking to balance the search for high-growth companies with fiscal care, the Growth at a Reasonable Price (GARP) or "affordable growth" strategy offers a practical middle path. This method seeks to find companies with solid, lasting growth paths but whose shares are not at extreme prices. It avoids the high risk of speculative, profitless growth while also steering clear of the stalled potential of inactive businesses. Filtering for stocks with strong growth marks, along with fair prices and good basic financial and profit condition, can reveal opportunities ready to provide returns as their growth stories develop and gain market notice.
One company that recently appeared through an affordable growth filter is TG Therapeutics Inc (NASDAQ:TGTX), a biopharmaceutical company centered on creating treatments for B-cell cancers and autoimmune diseases. The company’s main product, BRIUMVI®, an anti-CD20 monoclonal antibody for relapsing forms of multiple sclerosis, has led to a major commercial turning point, changing its financial picture.
Notable Growth Measures
The central idea of an affordable growth strategy is finding companies with significant expansion, and TG Therapeutics meets this clearly. The company’s basic report points to very strong recent results and a positive future view.
- Very Strong Past Growth: Over the last year, the company posted high growth rates, with Revenue rising by 87.32% and Earnings Per Share growing by 257.14%. This shows the effective market introduction and adoption of its key treatment.
- Positive Future Projections: Analysts forecast this pace to persist, with estimated average yearly EPS growth of about 53% and Revenue growth of close to 26% in the next few years. This forward potential is important for GARP investing, as it implies the growth narrative extends past a single period.
- Sector-Leading Profit Margins: Backing this growth is very good profitability at the margin level. TG Therapeutics has a Gross Margin of 83.66% and a Profit Margin of 72.56%, numbers that exceed most of its biotechnology industry counterparts. High margins supply resources for reinvestment and can offer protection during commercial operations.
Price Assessment in Perspective
A stock with high growth can still be a bad investment if its cost already accounts for years of future achievement. The affordable growth filter specifically looks for stocks that are "not overvalued," and TG Therapeutics shows a detailed price picture that tends toward fairness within its high-growth field.
- Varied Direct Price Assessment: On a direct basis, the company’s Price/Earnings (P/E) ratio of 67.06 seems high, particularly next to the wider S&P 500 average. This is typical for companies in a high-growth stage.
- Interesting Comparative Price: The essential perspective comes from industry comparison. TG Therapeutics’ P/E and, more significantly, its Price/Forward Earnings ratio of 20.85 are much lower than most of its biotechnology peers. This suggests the market may not completely value its growth relative to sector standards.
- Growth Adjustment: The Price/Earnings to Growth (PEG) ratio, which modifies the P/E for projected earnings growth, is noted as low. This measure is a key part of GARP review, as it aids in finding companies where the growth rate may support or even offset a higher earnings multiple.
Basic Financial and Profit Condition
An affordable growth strategy must confirm the growth rests on a steady base. A company with weak financial condition or irregular profitability is a higher-risk choice, regardless of its speed of growth. TG Therapeutics’ marks here are moderate but indicate important positives.
- Good Financial Condition (Score: 5/10): The company holds a solid cash position, with a Current Ratio of 4.10 and a Quick Ratio of 3.29, showing good ability to meet near-term needs. It has a workable debt level and a sound Altman-Z score, pointing to a low immediate risk of financial trouble.
- Satisfactory Profitability (Score: 5/10): While the profitability score is moderate, this is mainly because of the company's recent move to profitability. The basic margin measures, as mentioned, are very good. The report notes previous years of negative cash flow, which is normal for clinical-stage biotechs, but the present direction shows a clear change toward lasting earnings.
Summary
TG Therapeutics demonstrates the kind of opportunity an affordable growth filter aims to find: a company undergoing a strong, revenue-led change with projections for that growth to continue. While its price is not "low" in a conventional way, it seems fair, and even interesting, when judged against its own growth rate and the price of its industry group. The company’s sound balance sheet and very good margins supply a basic foundation for its expansion. For investors, it represents a possible position on the continued commercial performance of a recently launched treatment in a large market.
As with any filtering method, this single finding is a beginning for more detailed review. Investors can examine the full basic analysis report for TG Therapeutics for a more thorough look at all measures. Also, to find other companies that match this balanced view of growth and price, you can use the same Affordable Growth filter.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation to buy or sell any security, or an endorsement of any investment strategy. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.